Payment overview · 2025
General Payments
$79.50
5 reported records · 4 companies
Healthcare provider profile · identity verified
Gregory L Gibson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOILING SPRINGS, SC · NPI 1184695918
Verified facts
What the public records show
CMS Open Payments records show Gregory L Gibson, M.D. received $79.50 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.76 | 42.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.21 | 21.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.04 | 18.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.49 | 17.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.50 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 98 |
| Lisinopril | Lisinopril | 347 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 77 |
| Omeprazole | Omeprazole | 321 | 84 |
| Gabapentin | Gabapentin | 302 | 66 |
| Simvastatin | Simvastatin | 250 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 61 |
| Trazodone Hcl | Trazodone Hcl | 207 | 49 |
| Losartan Potassium | Losartan Potassium | 203 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 50 |
| Metformin Hcl Er | Metformin Hcl | 169 | 48 |
| Glimepiride | Glimepiride | 154 | 39 |
| Montelukast Sodium | Montelukast Sodium | 152 | 30 |
| Furosemide | Furosemide | 140 | 46 |
| Sertraline Hcl | Sertraline Hcl | 126 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 32 |
| Celecoxib | Celecoxib | 111 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 34 |
| Lorazepam | Lorazepam | 106 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 30 |
| Clonazepam | Clonazepam | 100 | 19 |
| Eliquis | Apixaban | 100 | 22 |
| Tramadol Hcl | Tramadol Hcl | 99 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 24 |
| Metformin Hcl | Metformin Hcl | 89 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 16 |
| Alendronate Sodium | Alendronate Sodium | 82 | 18 |
| Carvedilol | Carvedilol | 82 | 23 |
| Azithromycin | Azithromycin | 81 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 18 |
| Mirtazapine | Mirtazapine | 80 | 25 |
| Prednisone | Prednisone | 78 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 23 |
| Allopurinol | Allopurinol | 72 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 14 |
| Meloxicam | Meloxicam | 69 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 22 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Famotidine | Famotidine | 54 | 17 |
| Promethazine Hcl | Promethazine Hcl | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Diazepam | Diazepam | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 42 |
| Clonidine Hcl | Clonidine Hcl | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 16 |
| Cephalexin | Cephalexin | 48 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 17 |
| Potassium Chloride | Potassium Chloride | 46 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 35 | 24 |
| Atenolol | Atenolol | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 31 |
| Estradiol | Estradiol | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 17 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 25 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Colchicine | Colchicine | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.50 · 5 records | PFIZER INC. | ELIQUIS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error